Probuphine for treatment of opioid dependency
Presented By:
GOLAP Sk.
Roll no:- 19301913032
Reg no:- 131930210032
4th Year, Semester: 7th
Bengal School Of Technology, (A college of Pharmacy)
Hooghly ,West Bengal
2016

OPOID DEPENDENCY
Opioid dependency is a medical condition
that is characterized by the compulsive use
of opioids.
Opioids include substances:
 Morphine
Heroin
Codeine
Oxycodone

TYPES OF DOSAGE FORM
AVAILABLE
Tablet Petazocine 5 mg tab
Injection Naloxone 0.4-0.8 mg inj
Sublingual Buprenorphine 0.2-0.4 mg subli
Implant Buprenorphine 74.2 mg

Implants are the drug delivery systems which act
as reservoir of loaded drug and deliver it over a
period of time in a controlled manner upon
insertion into the body.
 INTRAMUSCULAR
 INTRACARNIAL
 SUBDERMAL

Probuphine
(buprenorphine; ethylene vinyl acetate)
Implantable formulation of buprenorphine
Properties of Individual Rods
• 80 mg BPN & ethylene vinyl acetate
• 26mm long & 2.5mm diameter rod
• Sustained release up to 6 month

General instruction:
Each dose consist of 4 implants inserted subdermally in the inner side of
the upper arm. Implant are intended to be in place for 6 month &
Removes implants by the end of the 6 month.
Dose & strengths:
Probuphine is a sterile ,single, off white ,soft, flexible ,rod shape
ethylene vinyl acetate[EVA] implant .74.2mg probuphine.

*

Mechanism of Action:
PROBUPHINE implants contain buprenorphine.
Buprenorphine is a partial agonist at the mu
opioid receptor and an antagonist at the kappa-
opioid receptor.

ADVERSE REACTIONS
Implant site pain
Headache
Constipation
Back pain
Allergic reaction
Vomiting
Infection at implant site

Long term treatment
One time invest
Very effective as
rehabitation
 Best choice for drug
addicted persons
 Potential selected
chronic diseases with
low dose
Costly
Skilled personnel required
For insertion & removal
Pain, irritation, swelling
Implant comes out by itself

Reference:
1. Breasted JG. Ancient Records of Egypt. University of Chicago Oriental Institute Publications, Vol. III, P.
217. University of Chicago Press, 1930.
Kiang TK, Epsom MH, Chang TK. UDP glucuronos yltransferase and clinical drug-drug interactions.
Pharmaco There 2005; 106:97-132
Behar, K.L., et al., 1999. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of
alcohol-dependent and hepatic encephalopathy patients. American Journal of Psychiatry 156(6):952-954
Breiter, H.C., et al., 1997. Acute effects of cocaine on human brain activity and emotion. Neuron 19(3):591-
611
Judd, L.L., et al., 1998. Effective medical treatment of opiate addiction. Journal of the American Medical
Association 280(22):1936-1943
 Ling W, Mooney L, Zhao M, et al. Selective review and commentary on emerging pharmacotherapies
 Rosenthal RN, Ling W, Casadonte P, et al. Buprenorphine implants for treatment of opioid dependence: Randomized
comparison to placebo and sublingual buprenorphine/ naloxone. Addiction, 2013;108(12
 ECRI Institute. AHRQ Healthcare Horizon Scanning System Potential High-Impact Interventions: Priority
Area 14: Substance Abuse. Prepared by ECRI Institute for AHRQ under Contract No.
HHSA290201000006C. Rockville, MD: Agency for Healthcare Research and Quality; December 2013
1. Rosenthal RN, Lowell MR, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among
Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized
Clinical Trial. JAMA. 2016;19:282-290.
Braeburn Pharma. Probuphine (buprenorphine) implant for sub dermal administration.
Prescribing Information. Reference ID: 3937415. Princeton, NJ: Braeburn Pharma; revised
May 2016.